Nuclear Medicine and Biology
Volume 34, Issue 4 , Pages 405-413 , May 2007

Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects

  • Roger E. McLendon

      Affiliations

    • Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 919 684 6940; fax: +1 919 681 7634.
    • ,
  • Gamal Akabani

      Affiliations

    • Department of Radiology, Duke University Medical Center, Durham, NC 27710, USA
    • ,
  • Henry S. Friedman

      Affiliations

    • Department of Pediatrics, Duke University Medical Center, Durham, NC 27710, USA
    • ,
  • David A. Reardon

      Affiliations

    • Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    • ,
  • Linda Cleveland

      Affiliations

    • Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA
    • ,
  • Ilkcan Cokgor

      Affiliations

    • Department of Pediatrics, Duke University Medical Center, Durham, NC 27710, USA
    • ,
  • James E. Herndon II

      Affiliations

    • Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, NC 27710, USA
    • ,
  • Carol Wikstrand

      Affiliations

    • Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA
    • ,
  • Susan T. Boulton

      Affiliations

    • Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    • ,
  • Allan H. Friedman

      Affiliations

    • Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    • ,
  • Darell D. Bigner

      Affiliations

    • Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA
    • ,
  • Michael R. Zalutsky

      Affiliations

    • Department of Radiology, Duke University Medical Center, Durham, NC 27710, USA

Received 25 October 2006 ,Revised 24 January 2007 ,Accepted 29 January 2007.

References 

  1. Zalutsky MR. Current status of therapy of solid tumors: brain tumor therapy. J Nucl Med. 2005;46(Suppl):151S–156S
  2. Burger PC, Boyko OB. The pathology of central nervous system radiation injury. In:  Gutin PH,  Leibel SA,  Sheline GE editor. Radiation injury to the central nervous system. New York: Raven Press; 1991;p. 191–208
  3. Burger PC, Mahley MS, Dudka L, Vogel FS. The morphologic effects of radiation administered therapeutically for intracranial gliomas: a postmortem study of 25 cases. Cancer. 1979;44:1256–1272
  4. Baglan RJ, Marks JE. Soft-tissue reactions following irradiation of primary brain and pituitary tumors. Int J Radiat Oncol Biol Phys. 1981;7:455–459
  5. Marks JE, Wong J. The risk of cerebral radionecrosis in relation to dose, time and fractionation. A follow-up study. Prog Exp Tumor Res. 1985;29:210–218
  6. Coffey RJ, Lunsford LD, Flickinger JC. The role of radiosurgery in the treatment of malignant brain tumors. Neurosurg Clin N Am. 1992;3:231–244
  7. Loeffler JS, Alexander E, Wen PY, Shea WM, Coleman CN, Kooy HM, et al. Results of stereotactic brachytherapy used in the initial management of patients with glioblastoma. J Natl Cancer Inst. 1990;82:1918–1921
  8. Malkin MG. Interstitial brachytherapy of malignant gliomas: the Memorial Sloan-Kettering Cancer Center experience. Recent Results Cancer Res. 1994;13:117–125
  9. Akabani G, Reist CJ, Cokgor I, Friedman AH, Friedman HS, Coleman RE, et al. Dosimetry of 131I-labeled 81C6 monoclonal antibody administered into surgically created resection cavities in patients with malignant brain tumors. J Nucl Med. 1999;40:631–638
  10. Akabani G, Cokgor I, Coleman RE, Gonzalez Trotter D, Wong TZ, Friedman HS, et al. Dosimetry and dose–response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy. Int J Radiat Oncol Biol Phys. 2000;46:947–958
  11. Bourdon MA, Wikstrand CJ, Furthmayr H, Matthews TJ, Bigner DD. Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody. Cancer Res. 1983;43:2796–2805
  12. Bourdon MA, Matthews TJ, Pizzo SV, Bigner DD. Immunochemical and biochemical characterization of a glioma-associated extracellular matrix glycoprotein. J Cell Biochem. 1985;28:183–195
  13. Ventimiglia JB, Wikstrand CJ, Ostrowski LE, Bourdon MA, Lightner VA, Bigner DD. Tenascin expression in human glioma cell lines and normal tissues. J Neuroimmunol. 1992;36:41–55
  14. Bigner DD, Brown MT, Friedman AH, Coleman RE, Akabani G, Friedman HS, et al. Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results. J Clin Oncol. 1998;16:2202–2212
  15. Hulette CM, Downey BT, Burger PC. Macrophage markers in diagnostic neuropathology. Am J Surg Pathol. 1992;16:493–499
  16. Brandtzaeg P, Jones DB, Flavell DJ, Fagerhol MK. Mac 387 antibody and detection of formalin resistant myelomonocytic L1 antigen. J Clin Pathol. 1988;41:963–970
  17. Wikstrand CJ, Fung KM, Trajanowski JQ, McLendon RE, Bigner DD. In:  Bigner DD,  Rosemblum M,  Brunner JM editor. Russell and Rubinstein's pathology of tumors of the nervous system. London: Edward Arnold; 1998;p. 251–306
  18. Forsyth PA, Kelly PJ, Cascino TL, Scheithauer BW, Shaw EG, Dinapoli RP, et al. Radiation necrosis or glioma recurrence: is computer-assisted stereotactic biopsy useful?. J Neurosurg. 1995;82:436–444
  19. Zalutsky MR. Radionuclide therapy. In:  Roesch F editors. Handbook of nuclear chemistry, Volume 4: Radiochemistry and radiopharmaceutical chemistry in life sciences. Dordrecht: Kluwer Academic; 2003;p. 315–348
  20. Marriott CJ, Thorstad W, Akabani G, Brown MT, McLendon RE, Hanson MW, et al. Locally increased uptake of fluorine-18-fluorodeoxyglucose after intracavitary administration of iodine-131-labeled antibody for primary brain tumors. J Nucl Med. 1998;39:1376–1380
  21. Papanastassiou V, Pizer BL, Coakham HB, Bullimore J, Zananiri T, Kemshead JT. Treatment of recurrent and cystic malignant gliomas by a single intracavity injection of 131I monoclonal antibody: feasibility, pharmacokinetics and dosimetry. Br J Cancer. 1993;67:144–151
  22. Hopkins K, Papanastassiou V, Kemshead JT. The treatment of patients with recurrent malignant gliomas with intratumoral radioimmunoconjugates. Recent Results Cancer Res. 1996;141:159–175
  23. Riva P, Arista A, Sturiale C, Moscatelli G, Tison V, Mariani M, et al. Treatment of intracranial human glioblastoma by direct intratumoral administration of 131I-labelled anti-tenascin monoclonal antibody BC-2. Int J Cancer. 1992;51:7–13
  24. Riva P, Franceschi G, Frattarelli M, Lazzari S, Riva N, Giuliani G, et al. Loco-regional radioimmunotherapy of high-grade malignant gliomas using specific monoclonal antibodies labeled with 90Y: a phase I study. Clin Cancer Res. 1999;5:3275s–3280s
  25. Miot E, Hoffschir D, Alapetite C, Gaboriaud G, Pontvert D, Fetissof F, et al. Experimental MR study of cerebral radiation injury: quantitative T2 changes over time and histopathologic correlation. AJNR Am J Neuroradiol. 1995;16:79–85
  26. Bernstein M, Marotta T, Stewart P, Glen J, Resch L, Henkelman M. Brain damage from 125I brachytherapy evaluated by MR imaging, a blood–brain barrier tracer, and light and electron microscopy in a rat model. J Neurosurg. 1990;73:585–593
  27. Price RA, Birdwell DA. The central nervous system in childhood leukemia: III. Mineralizing microangiopathy and dystrophic mineralization. Cancer. 1978;42:717–728
  28. Matsumoto K, Nakagawa M, Higashi H, Maeshiro T, Tsuno K, Mishima N, et al. Preliminary results of interstitial 192Ir brachytherapy for malignant gliomas. Neurol Med Chir (Tokyo). 1992;32:739–746
  29. Fajardo LF, Berthrong M, Anderson RE. In: Radiation pathology. New York: Oxford University Press; 2001;p. 351–361

PII: S0969-8051(07)00036-4

doi: 10.1016/j.nucmedbio.2007.01.009

Nuclear Medicine and Biology
Volume 34, Issue 4 , Pages 405-413 , May 2007

Article Tools

* Image Usage & Resolution